Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 46.10 yuan, representing a 102.46% increase on the first day of trading [1] Company Overview - Hanbang Technology focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, and technical solutions [1] - The company is controlled by Zhang Dabin, who holds 23.75% of the shares directly and has a total control of 28.94% post-IPO [1] IPO Details - The company issued 22,000,000 shares at a price of 22.77 yuan per share, raising a total of 500.94 million yuan, with a net amount of 430.67 million yuan after deducting issuance costs [4] - The total issuance costs amounted to 70.27 million yuan, with underwriting fees of 37.29 million yuan [6] Financial Performance - For the years 2022 to 2024, the company reported revenues of 481.79 million yuan, 619.01 million yuan, and 690.88 million yuan, respectively, with net profits of 38.56 million yuan, 51.50 million yuan, and 79.34 million yuan [6][7] - In the first quarter of 2025, the company achieved total revenue of 165.23 million yuan, a year-on-year increase of 19.88%, and a net profit of 11.10 million yuan, up 93.79% from the previous year [9][10] Project Funding Allocation - The raised funds will be allocated to three main projects: 1. Annual production of 1,000 units of liquid chromatography separation equipment (19.30 million yuan) 2. Construction of a chromatography separation equipment R&D center (27.11 million yuan) 3. Annual production of 2,000 units of laboratory chromatography separation and purification instruments (22.48 million yuan) [5]

Core Viewpoint - Hanbang Technology is a high-tech enterprise focusing on chromatography technology, providing professional separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1][2]. Company Overview - Hanbang Technology has been deeply engaged in the pharmaceutical equipment industry for nearly 30 years and has become one of the main manufacturers of domestic drug purification equipment [2]. - The company has sold products to over 2,000 clients domestically and internationally, including well-known pharmaceutical companies such as Heng Rui Medicine, Zhengda Tianqing, and others in countries like Germany, the UK, India, South Korea, and Norway [2]. Product and Technology - The company has achieved breakthroughs in separation and purification technology, enabling linear scale-up of products from gram-level to kilogram-level [1]. - Hanbang Technology's products and technologies are widely used in the research and production of various drugs and natural products, including antibodies, recombinant proteins, vaccines, insulin, peptides, contrast agents, and antibiotics [1]. Future Strategy - The company aims to continue focusing on its core chromatography product business, enhancing technological research and innovation, and expanding product varieties and performance based on market demand [2]. - Hanbang Technology's mission is to contribute to the domestic development of chromatography separation and purification equipment and the industrial upgrading of the downstream pharmaceutical industry, with the goal of becoming the leading brand in the international chromatography industry [2].